Olfactory impairment is related to tau pathology and neuroinflammation in Alzheimer’s disease
Manuscript Number:
20-1149R1
Author(s):
Adam M. Brickman, D. P. Devanand, Lawrence S. Honig, Aubrey Johnson, Julia Klein, William Charles Kreisl, Seonjoo Lee, Krista Polly, Yaakov Stern, Zeljko Tomljanovic, Xinyu Yan, James Zou
Disclosures
Adam M. Brickman
Consulting Fees:
Consultation for Cognition Therapeutics, unrelated to topic of paper.
Consultation for Regeneron Therapeutics, unrelated to topic of paper.
Data safety monitoring board, Albert Einstein College of Medicine
Equity:
Venus Medtech via Mars Holding Ltd.
Patents/Royalties
Past legal consultation.
US patent number 9867566
Patent pending publication number 20180228422
Grants
Agency:
Mars Symbioscience
Dates:
2016-present
D. P. Devanand
Consulting Fees:
Scientific Adviser: Acadia, Eisai, Genentech, Sunovion, BXCel.
DSMB: Green Valley
Consulting: Cerveau Technologies, Roche, Novartis, Takeda
Received less than $5,000 from any one company in the last year and expect to receive less than $5,000 for any one company in the next year.
Scientific Review Board: Alzheimer's Drug Discovery Foundation
Honorarium of $250.
Seonjoo Lee
Nothing to Disclose
Krista Polly
Nothing to Disclose
Yaakov Stern
Consulting Fees:
Consulting for Eisai, Lilly, Arcadia
Patents/Royalties
Columbia University licenses the Dependence Scale, and in accordance with University policy, Dr. Stern is entitled to royalties through this license